FIB-4 Predicts MACE and Cardiovascular Mortality in Patients With Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally and is estimated to affect one-third of the global population.1 Cardiovascular disease (CVD) remains the leading cause of mortality for NAFLD because it is closely associated with atherogenic dyslipidemia resulting in the formation of coronary plaques.1 In a recent meta-analysis it was estimated that 44.6% have coronary heart disease and concurrent structural heart changes can also occur resulting in diastolic dysfunction in patients with NAFLD.